Once again, attempts are in progress to receive reimbursement for 'Vyndamax,' a new drug for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Industry sources said that Pfizer Korea had recently submitted an application for the reimbursement of its new ATTR-CM drug, Vyndamax (tafamidis 61mg). This time, the company conducted the PE assessment and aims to receive reimbursement through the risk-sharing agreement (RSA) scheme.

After failing to receive designation as an essential drug earlier this year, the company has quickly supplemented the data to try for reimbursement once again, which shows the company’s determination to be listed for reimbursement.